- Home
- BRKL vs CDNA Comparison
BRKL vs CDNA Comparison
Compare BRKL & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRKL
- CDNA
- Stock Information
- Founded
- BRKL 1871
- CDNA 1998
- Country
- BRKL United States
- CDNA United States
- Employees
- BRKL N/A
- CDNA N/A
- Industry
- BRKL Savings Institutions
- CDNA Medical Specialities
- Sector
- BRKL Finance
- CDNA Health Care
- Exchange
- BRKL Nasdaq
- CDNA Nasdaq
- Market Cap
- BRKL 897.3M
- CDNA 844.7M
- IPO Year
- BRKL 1998
- CDNA 2014
- Fundamental
- Price
- BRKL $11.00
- CDNA $16.06
- Analyst Decision
- BRKL Buy
- CDNA Buy
- Analyst Count
- BRKL 2
- CDNA 7
- Target Price
- BRKL $15.25
- CDNA $30.33
- AVG Volume (30 Days)
- BRKL 489.3K
- CDNA 1.2M
- Earning Date
- BRKL 04-23-2025
- CDNA 04-30-2025
- Dividend Yield
- BRKL 4.87%
- CDNA N/A
- EPS Growth
- BRKL N/A
- CDNA N/A
- EPS
- BRKL 0.82
- CDNA 1.07
- Revenue
- BRKL $338,567,000.00
- CDNA $346,421,000.00
- Revenue This Year
- BRKL $55.27
- CDNA $13.37
- Revenue Next Year
- BRKL $37.40
- CDNA $15.28
- P/E Ratio
- BRKL $13.39
- CDNA $15.23
- Revenue Growth
- BRKL N/A
- CDNA 25.92
- 52 Week Low
- BRKL $8.01
- CDNA $7.42
- 52 Week High
- BRKL $13.15
- CDNA $34.84
- Technical
- Relative Strength Index (RSI)
- BRKL 60.67
- CDNA 44.83
- Support Level
- BRKL $10.50
- CDNA $14.09
- Resistance Level
- BRKL $11.17
- CDNA $18.71
- Average True Range (ATR)
- BRKL 0.22
- CDNA 0.97
- MACD
- BRKL 0.10
- CDNA 0.01
- Stochastic Oscillator
- BRKL 85.92
- CDNA 44.16
About BRKL Brookline Bancorp Inc.
Brookline Bancorp Inc operates as a multi-bank holding company. It offers commercial, business, and retail banking services, including a full complement of cash management products, online banking services, and consumer and residential loans.
About CDNA CareDx Inc.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.